Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population
van der Linden, Noreen, Klinkenberg, Lieke J. J., Bekers, Otto, van Loon, Luc, Van Dieijen-Visser, Marja P., Zeegers, Maurice P. and Meex, Steven J. R.. (2016). Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population. Medicine. https://doi.org/10.1097/MD.0000000000005703
|Authors||van der Linden, Noreen, Klinkenberg, Lieke J. J., Bekers, Otto, van Loon, Luc, Van Dieijen-Visser, Marja P., Zeegers, Maurice P. and Meex, Steven J. R.|
Interest in the use of cardiac troponin T (cTnT) and cardiac troponin I (cTnI) has expanded from diagnosis of acute myocardial infarction to risk assessment for morbidity and mortality. Although cTnT and cTnI were shown to have equivalent diagnostic performance in the setting of suspected acute myocardial infarction, potential prognostic differences are largely unexplored. The aim of this study is to quantify and compare the relationship between cTnT and cTnI, and cardiovascular and all-cause mortality in the general population. Medline, Embase, and the Cochrane Library (from inception through October 2016) were searched for prospective observational cohort studies reporting on the prognostic value of basal high-sensitive cTnT and/or cTnI levels on cardiovascular and all-cause mortality in the general population. Data on study characteristics, participants' characteristics, outcome parameters, and quality [according to the Effective Public Health Practice Project (EPHPP) "Quality Assessment Tool For Quantitative Studies] were retrieved. Hazard ratios per standard deviation increase in basal cardiac troponin level (HR per 1-SD; retrieved from the included articles or estimated) were pooled using a random-effects model. On a total of 2585 reviewed citations, 11 studies, with data on 65,019 participants, were included in the meta-analysis. Random effects pooling showed significant associations between basal cardiac troponin levels and HR for cardiovascular and all-cause mortality [HR per 1-SD 1.29 (95% confidence interval, 95% CI, 1.20-1.38) and HR per 1-SD 1.18 (95% CI, 1.11-1.26), respectively]. Stratified analyses showed higher HRs for cTnT than cTnI [cardiovascular mortality: cTnT HR per 1-SD 1.37 (95% CI, 1.23-1.52); and cTnI HR per 1-SD 1.21 (95% CI, 1.16-1.26); all-cause mortality: cTnT HR per 1-SD 1.31 (955 CI, 1.13-1.53); and cTnI HR per 1-SD 1.14 (95% CI, 1.06-1.22)]. These differences were significant (P < 0.01) in meta-regression analyses for cardiovascular mortality but did not reach statistical significance for all-cause mortality. Elevated, basal cTnT, and cTnI show robust associations with an increased risk of cardiovascular and all-cause mortality during follow-up in the general population.
|Keywords||biomarker; cardiac troponin; meta-analysis; mortality; survival|
|Publisher||Wolters Kluwer Health|
|Digital Object Identifier (DOI)||https://doi.org/10.1097/MD.0000000000005703|
|Open access||Open access|
|Research Group||Mary MacKillop Institute for Health Research|
Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
|Place of publication||United States of America|
0views this month
1downloads this month